City of Hope Awarded $8 Million to Launch Stem Cell Therapy Clinic
News Nov 07, 2014
Identifying cures for currently incurable diseases and providing patients safe, fast, and potentially life-saving treatments is the focus of City of Hope’s new Alpha Clinic for Cell Therapy and Innovation (ACT-I).
The clinic is funded by an $8 million, 5-year grant from the California Institute for Regenerative Medicine. The award is part of CIRM’s Alpha Stem Cell Clinics program, which aims to create one-stop centers for clinical trials focused on stem cell treatments for diseases.
Two trials were identified to launch the ACT-I center but additional trials are currently enrolling patients and will be part of this clinic. These include transplants of blood stem cells that have been modified to treat patients with AIDS and lymphoma; neural stem cells – which naturally home to cancer cells – to deliver drugs directly to cancers hiding in the brain; and T cell immunotherapy trials developed by researchers in City of Hope’s new Hematologic Malignancies and Stem Cell Transplantation Institute.
“We are committed to finding cures and treatments to diseases that are, for now, incurable,” said John Zaia, the Aaron D. and Edith Miller Chair in Gene Therapy, chair of the Department of Virology, and principal investigator for the stem cell clinic. “This grant recognizes City of Hope’s commitment to and leadership in this endeavor, as well as enables us to pursue the crucially important work of bringing the promising potential of stem cell treatments to fruition.”
In addition to the Alpha Stem Cell Clinic grant, City of Hope has previously been awarded more than $55 million in CIRM funds for laboratory and translational research primarily in HIV/AIDS and brain cancer.
City of Hope scientists are investigating two different means of altering stem cells to fight AIDS. One approach is a combination of stem cell and gene therapy using small ribonucleic – or RNA – molecules that block the genes HIV needs to infect immune cells, specifically T cells. Developed by John Rossi, Ph.D., Lidow Family Research Chair and chair of the Department of Molecular and Cell Biology, this approach aims to spur to spur the immune systems to produce T cells resistant to HIV by infusing the patient with these altered stem cells.
Another approach uses an enzyme called a zinc-finger nuclease, or ZFN, as a pair of molecular scissor that can edit the HIV patient’s stem cell genes so they no longer produce a key protein the virus requires to infect cells. This approach has been developed by a team of investigators at City of Hope working with Sangamo Biosciences and Keck School of Medicine at USC.
Karen Aboody, M.D., professor in the Department of Neurosciences and Division of Neurosurgery, co-leader of the Developmental Cancer Therapeutics Program and principal investigator of a CIRM Disease Team Award, in collaboration with Jana Portnow, M.D., associate professor of Medical Oncology and associate director of the Brain Tumor Program, developed a neural stem cell platform for targeting cancer drugs selectively to tumor sites, potentially increasing efficacy and decreasing side effects. This platform also will be available through clinical trials offered by the Alpha Clinic. In previous laboratory and first-in-human safety trials, Aboody and her team established that neural stem cells genetically modified to express a therapeutic enzyme migrated to cancer cells. These enzymes could then convert a prodrug – a benign form of a drug – into a potent cancer-killing drug at the tumor site. The prodrug itself can cross the blood-brain barrier which blocks most chemotherapy drugs, one of the challenges of treating brain cancers.
In addition to these trials, the new clinic will eventually help advance T cell immunotherapies being developed for a number of cancers through the Hematologic Malignancies and Stem Cell Transplantation Institute, led by Stephen J. Forman, director of the T Cell Immunotherapy Research Institute. Researchers are exploring treating a variety of cancers using a similar approach: Patients have their T cells collected from the blood then modified using a lentivirus – a retrovirus which encodes the tumor recognition information into the T cell. The modified cells are able to identify receptors found on cancer cells – and, researchers believe, the immune system will now be able to fight the cancer.
City of Hope’s proposal was the most highly ranked application for this round of Alpha Stem Cell Clinic Awards in which the top 3 projects were scored.
“Everything we do has one simple goal, to accelerate the development of successful treatments for people in need,” said C. Randal Mills, Ph.D., president and CEO of the stem cell agency. “Stem cell therapies are a new way of treating disease; instead of managing symptoms, cellular medicine has the power to replace or regenerate damaged tissue and organs. And so we need to explore new and innovate ways of accelerating clinical research with stem cells. That is what we hope these Alpha Stem Cell Clinics will accomplish.”
Antitumor Immune Function in Liver Controlled by Gut MicrobiomeNews
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. The study showed that bacteria found in the gut of mice affect the liver’s antitumor immune function. The findings have implications for understanding the mechanisms that lead to liver cancer and for therapeutic approaches to treat them.READ MORE
You Are What Your Mother EatsNews
While many factors, such as the age of the mother, overall health and genetics ultimately play a role, the correlation between a mother’s nutrition habits and metabolism has been proved to directly impact the growth of her child. And researchers believe they may be one step closer to knowing why.READ MORE
How Hematopoietic Stem Cells Balance Activation and DormancyNews
Researchers have shown how intracellular signalling can safeguard the delicate balance between hematopoietic stem cell activation and dormancy.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018